



Sagent – Recall of phenylephrine injection

- On March 11, 2021, [Sagent announced](#) a voluntary, user-level recall of three lots of [phenylephrine injection](#) as the result of a customer complaint due to potentially loose crimped vial overseals. A non-integral crimped vial overseal may result in a non-sterile product.
 - Clinical Services, through the Drug Safety Notification program, did not identify any members that may be affected by this recall. Mailings will not be conducted.
 - Other lots of phenylephrine injection are available for patients to use.
- The lot numbers being recalled were distributed to hospitals, wholesalers and distributors nationwide in the U.S. from 11/17/2020 - 3/08/2021.

Product Description	NDC#	Lot# (Expiration Date)
Phenylephrine hydrochloride injection	25021-315-01	PHT8IB2 (8/2022), PHT9IB2 (8/2022), PHT1JB2 (9/2022)

- Phenylephrine injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important low blood pressure resulting primarily from the dilation of blood vessels, which decreases blood pressure in the setting of anesthesia.
- Intravenous administration of a product intended to be sterile that is not sterile could result in serious systemic infections which may be life-threatening. The possibility of a breach in sterility assurance in distributed product, while remote, cannot be eliminated.
- To date, Sagent has not received reports of any adverse events associated with this issue.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled phenylephrine injection.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- Contact Sagent at **1-866-625-1618** for more information about this recall.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.